← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab and Recombinant Human Hyaluronidase)

Recurrent Multiple Myeloma; Refractory Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+4
효능 ORR 39.4%임상시험 25상태 RECRUITING
CGTBiologicstaleDompé Farmaceutici S.p.APhase 1

Ex-Vivo expanded autologous IL-8 receptor (CXCR2, Ex-Vivo expanded autologous IL-8 receptor, Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells)

Brain Metastases · Glioblastoma Multiforme

#GlioblastomaMultiforme#CGT#Phase1#세포유전치료#CAR-T+3
효능 ORR 5.7%임상시험 25상태 RECRUITING
ADCBiologicNational Cancer Institute (NCI)vedotin, and venetoclax dem…Phase 2

Larotrectinib (Larotrectinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 94.4%임상시험 25상태 RECRUITING
AntibodystaleGalderma R&DApproved

Nemolizumab (Nemolizumab)

Psoriasis; Atopic Dermatitis · Psoriasis

#Psoriasis#Antibody#Approved#항체#면역항체+3
임상시험 25상태 RECRUITING
ADCBiologicstaleHoffmann-La RochePhase 2

POLA-R-CHP (POLA-R-CHP)

Diffuse Large B Cell Lymphoma (DLBCL) · Diffuse Large B-Cell Lymphoma (DLBCL)

#DiffuseLargeB-CellLymphomaDLBCL#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 95%임상시험 25상태 RECRUITING
ADCBiologicstaleShanghai Hengrui Pharmaceutical…Phase 2

SHR-A2102 (SHR-A2102)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 25상태 RECRUITING
CGTBiologicstaleNkarta, Inc.Phase 2

allogeneic, donor-derived NK cells (allogeneic, donor-derived NK cells)

Acute Myelogenous Leukemia · Acute Myelogenous Leukemia

#AcuteMyelogenousLeukemia#CGT#Phase2#세포유전치료#CAR-T+2
효능 ORR 4%임상시험 25상태 DISCONTINUED
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

ARV-471 (ARV-471)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 0%임상시험 24상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

AZD2936 (AZD2936)

Advanced or Metastatic NSCLC · Advanced or Metastatic NSCLC

#AdvancedorMetastaticNSCLC#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 24상태 RECRUITING
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin - induction)

Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 2%임상시험 24상태 ACTIVE
ADCBiologicstaleGlaxoSmithKlinePhase 2

Dabrafenib Mesylate (Dabrafenib Mesylate)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 61%임상시험 24상태 RECRUITING
AntibodystaleJanssenPhase 1

daratumumab (Darzalex, Daratumumab/rHuPH20)

Multiple Myeloma; Non-Hodgkin Lymphoma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase1#항체#면역항체+3
효능 ORR 39.4%임상시험 24상태 ACTIVE
ADCBiologicstaleDaiichi SankyoPhase 1

FL-DP (HER3-DXd, HER3-DXd (FL-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 24상태 RECRUITING
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

PLX3397 (PLX3397)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 33.3%임상시험 24상태 RECRUITING
ADCBiologicstaleSpectrum Pharmaceuticals, IncPhase 1

Poziotinib (Poziotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 30%임상시험 24상태 DISCONTINUED
ADCBiologicstaleGileadPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Sacituzumab Govitecan / Trastuzumab Deruxtecan)

Triple Negative Breast Neoplasms; Neoplasm Metastasis · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 44%임상시험 24상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

U3-1402 (U3-1402)

Metastatic Breast Cancer; Advanced Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 24상태 ACTIVE
ADCBiologicstaleByondis B.V.Phase 3

trastuzumab (Herceptin, vic-, (vic-)trastuzumab duocarmazine)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 27.8%임상시험 23상태 ACTIVE
AntibodystaleRegeneronPhase 2

Cemiplimab plus REGN3767 (Cemiplimab plus REGN3767)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 23상태 RECRUITING
ADCBiologicstaleTaiho Oncology, Inc.Phase 2

Futibatinib (Futibatinib)

Advanced Solid Tumor · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 47.1%임상시험 23상태 RECRUITING

38 / 209 페이지

← 이전다음 →